MALVERN, Pa., Sept. 10, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis ...
MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during ...
DUBLIN, March 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today announced top-line results from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in ...
MALVERN, Pa. - Endo, Inc. (OTCQX:NDOI), a $1.6 billion pharmaceutical company currently trading near its 52-week low, announced Thursday that it is presenting three studies related to plantar ...
MALVERN, Pa., Sept. 10, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that two presentations related to plantar fibromatosis (PFI) and plantar fasciitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results